[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619816":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":36,"locations":42,"responsibleParty":116,"collaborators":28,"id":118,"slug":28,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":28,"eligibilityCriteria":123,"healthyVolunteers":119,"sex":124,"minAge":125,"maxAge":28,"enrollmentInfo":126,"targetDuration":28,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":144,"overallStatus":45,"whyStopped":28,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},{"fullName":5,"class":6},"Revolution Medicines, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: RMC-5127 Monotherapy","EXPERIMENTAL","Dose Escalation and Dose Expansion",[13],"Drug: RMC-5127",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm B: RMC-5127 + Daraxonrasib Combination",[13,17],"Drug: daraxonrasib",{"label":19,"type":10,"description":11,"interventionNames":20},"Arm C: RMC-5127 + Cetuximab Combination",[13,21],"Drug: cetuximab",[23,29,32],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","RMC-5127","oral tablets",[9,15,19],null,{"type":24,"name":30,"description":26,"armGroupLabels":31,"otherNames":28},"daraxonrasib",[15],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":28},"cetuximab","IV infusion",[19],[37],{"name":38,"role":39,"phone":40,"phoneExt":28,"email":41},"Revolution Medicines Study Director","CONTACT","1-844-2-REVMED","medinfo@revmed.com",[43,62,77,91,101],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"START Midwest","RECRUITING","Grand Rapids","Michigan","49546","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-85.66809,42.96336,{"lat":55,"lon":54},[58],{"name":28,"role":39,"phone":59,"phoneExt":60,"email":61},"616-954-5554","ext. 4","hopeteam@startresearch.com",{"facility":63,"status":45,"city":64,"state":65,"zip":66,"country":49,"countryCode":50,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"NEXT - Dallas","Dallas","Texas","75039",{"type":52,"coordinates":68},[69,70],-96.80667,32.78306,{"lat":70,"lon":69},[73],{"name":74,"role":39,"phone":75,"phoneExt":28,"email":76},"NEXT TXReferrels","972-893-8800","NXT_TXReferrals@nextoncology.com",{"facility":78,"status":45,"city":79,"state":65,"zip":80,"country":49,"countryCode":50,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"NEXT","San Antonio","78229",{"type":52,"coordinates":82},[83,84],-98.49363,29.42412,{"lat":84,"lon":83},[87],{"name":88,"role":39,"phone":89,"phoneExt":28,"email":90},"Jordan Georg","210-580-9521","jgeorg@nextoncology.com",{"facility":92,"status":45,"city":79,"state":65,"zip":80,"country":49,"countryCode":50,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},"START - San Antonio",{"type":52,"coordinates":94},[83,84],{"lat":84,"lon":83},[97],{"name":98,"role":39,"phone":99,"phoneExt":28,"email":100},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"facility":102,"status":45,"city":103,"state":104,"zip":105,"country":49,"countryCode":50,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"NEXT - Virginia","Fairfax","Virginia","22031",{"type":52,"coordinates":107},[108,109],-77.30637,38.84622,{"lat":109,"lon":108},[112],{"name":113,"role":39,"phone":114,"phoneExt":28,"email":115},"Paolo Umayam","703-783-4546","pumayam@nextoncology.com",{"type":117,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100619816",false,"NCT07349537","Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Phase 1\u002F1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.\n* Measurable per RECIST v1.1\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and\u002For inhibitors).\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to receiving study drug(s).\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.","ALL","18 Years",{"count":127,"type":128},574,"ESTIMATED","INTERVENTIONAL",[131],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.",[134,135,136,137,138,139,140,141,142,143],"Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","PDAC","CRC","NSCLC","Pancreatic Cancer","Lung Cancer (NSCLC)","Advanced Solid Tumors",[143,141,145,138,146,139,147,148,140,149,150,151],"Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","Lung Cancer","Non-small Cell Lung Cancer","RAS","KRAS","RAS Mutation","2026-05-28",{"date":154,"type":155},"2026-06-01","ACTUAL",{"date":157,"type":155},"2026-01-08",{"date":159,"type":128},"2028-10",{"name":5,"class":6},5]